anidulafungin has been researched along with Benign Neoplasms in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 3 (42.86) | 2.80 |
| Authors | Studies |
|---|---|
| Albert, N; Chamilos, G; Kontoyiannis, DP; Lewis, RE | 1 |
| Enersen, M; Fjeld, KG; Gay, CL; Herlofson, BB; Hove, LH; Kristoffersen, AK; Lerdal, A; Monsen, RE; Nordgarden, H; Tollisen, A | 1 |
| Abastabar, M; Badiee, P; Haghani, I; Mohammadi, R; Morovati, H; Noorbakhsh, M; Sharifi, M | 1 |
| Aram, JA; Busca, A; Capparella, MR; De Rosa, FG; Yan, JL | 1 |
| Jiang, Y; Jung, DS; Kontoyiannis, DP; Tverdek, FP | 1 |
| Cuenca-Estrella, M; Gurguí, M | 1 |
| Chiou, CC; Groll, AH; Walsh, TJ | 1 |
3 review(s) available for anidulafungin and Benign Neoplasms
| Article | Year |
|---|---|
Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies.
Topics: Administration, Intravenous; Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Fluconazole; Humans; Neoplasms; Treatment Outcome; Voriconazole | 2021 |
[Current status of invasive fungal infections. New diagnostic techniques and antifungal agents].
Topics: Anidulafungin; Antifungal Agents; Aspergillosis; beta-Glucans; Candidiasis; Clinical Trials as Topic; Critical Care; Diabetes Complications; Disease Susceptibility; Echinocandins; Fungemia; Galactose; Hematologic Diseases; Humans; Immunocompromised Host; Mannans; Meta-Analysis as Topic; Mycoses; Neoplasms; Opportunistic Infections | 2008 |
New drugs and novel targets for treatment of invasive fungal infections in patients with cancer.
Topics: Anidulafungin; Antifungal Agents; Echinocandins; Humans; Immunocompromised Host; Lipopeptides; Lipoproteins; Micafungin; Mycoses; Neoplasms; Opportunistic Infections; Peptides, Cyclic; Pyrimidines; Triazoles; Voriconazole | 2000 |
4 other study(ies) available for anidulafungin and Benign Neoplasms
| Article | Year |
|---|---|
Paradoxical effect of Echinocandins across Candida species in vitro: evidence for echinocandin-specific and candida species-related differences.
Topics: Antifungal Agents; Candida; Candidiasis; Culture Media; Fungemia; Humans; Microbial Sensitivity Tests; Neoplasms; Peptides, Cyclic; Species Specificity | 2007 |
Identification and susceptibility testing of oral candidiasis in advanced cancer patients.
Topics: Amphotericin B; Anidulafungin; Antifungal Agents; Candida; Candida albicans; Candidiasis, Oral; Drug Resistance, Fungal; Fluconazole; Humans; Microbial Sensitivity Tests; Neoplasms | 2023 |
A 3-year study of
Topics: Amphotericin B; Anidulafungin; Antifungal Agents; Candida; Candidemia; Candidiasis; Drug Resistance, Fungal; Fluconazole; Humans; Itraconazole; Microbial Sensitivity Tests; Neoplasms | 2023 |
Switching to anidulafungin from caspofungin in cancer patients in the setting of liver dysfunction is associated with improvement of liver function tests.
Topics: Adult; Aged; Aged, 80 and over; Anidulafungin; Caspofungin; Chemical and Drug Induced Liver Injury; Drug-Related Side Effects and Adverse Reactions; Echinocandins; Female; Humans; Lipopeptides; Liver Function Tests; Male; Middle Aged; Mycoses; Neoplasms; Retrospective Studies; Young Adult | 2015 |